Volume 20 Issue 5
May  2022
Turn off MathJax
Article Contents
LI Xiu-yi, QI Xiang-ming, XIA Yuan-yuan, LUO Rui, HAN Shu-wei, YU Xiao-qin. Clinical value of serum human epididymal protein 4 in the diagnosis of chronic kidney disease[J]. Chinese Journal of General Practice, 2022, 20(5): 789-792. doi: 10.16766/j.cnki.issn.1674-4152.002455
Citation: LI Xiu-yi, QI Xiang-ming, XIA Yuan-yuan, LUO Rui, HAN Shu-wei, YU Xiao-qin. Clinical value of serum human epididymal protein 4 in the diagnosis of chronic kidney disease[J]. Chinese Journal of General Practice, 2022, 20(5): 789-792. doi: 10.16766/j.cnki.issn.1674-4152.002455

Clinical value of serum human epididymal protein 4 in the diagnosis of chronic kidney disease

doi: 10.16766/j.cnki.issn.1674-4152.002455
Funds:

 1908085MH245

  • Received Date: 2021-11-11
    Available Online: 2022-09-05
  •   Objective  To investigate the clinical diagnostic value of serum human epididymal protein 4 (HE4) in chronic kidney disease (CKD) and different stages.  Methods  A total of 117 patients with CKD admitted to the Department of Nephrology of Hefei First People's Hospital from February 2019 to September 2020 were selected as the observation group, and 78 healthy patients with the same age during the same period were selected as the control group. The expression levels of serum HE4, urea nitrogen (BUN), creatinine (SCr), cystatin C (CysC) and retinol-binding protein (RBP) in the subjects of the two groups were detected to observe the correlation and clinical diagnostic value of CKD.  Results  The expression levels of serum HE4, BUN, SCr, CysC and RBP in the CKD group were significantly higher than those in the control group (all P < 0.01). As the CKD stage of the patients increased, no significant difference in the early grouping of BUN, SCr and RBP was found compared with the control group in each stage of CKD and the control group (all P>0.05). The other staging groups were compared with the control group, and the differences were statistically significant (all P < 0.01). The comparison amongst the CKD 1 - 5 staging groups revealed that the HE4, CysC and RBP groups had statistically significant differences (all P < 0.05), and BUN and SCr were significantly different (all P < 0.05). Compared between groups, there was no significant difference between CKD 1 and CKD 2 (all P>0.05), and significant differences were noted between the CKD 3 and CKD 5 groups and compared with CKD 1 to CKD 2 (all P < 0.01). The expression level of serum HE4 was negatively correlated with eGFR but positively correlated with BUN, SCr, CysC and RBP. ROC analysis showed that the area under the curve of HE4 (AUC=0.978) was significantly better than that of Bun (AUC=0.956), SCr (AUC=0.973), CysC (AUC=0.992) and RBP (AUC=0.910).  Conclusion  The serum HE4 level is related to the occurrence and development of CKD, and it has certain clinical significance for the staging of CKD. Serum HE4 is expected to function as a new serum biological diagnostic marker for the progression and prognosis of CKD.

     

  • loading
  • [1]
    LIU Y, LI M Y, SONG Y X, et al. Association of serum bilirubin with renal outcomes in Han Chinese patients with chronic kidney disease[J]. Clinica Chimica Acta, 2018, 480: 9-16. doi: 10.1016/j.cca.2018.01.041
    [2]
    TARR M C, HINGORANI S R. Prematurity and future kidney health: The growing risk of chronic kidney disease[J]. Curr Opin Pediatr, 2018, 30(2): 1-8.
    [3]
    李财昌, 周萍, 王顺, 等. 重症医学科患者急性肾损伤的临床特点分析[J]. 新疆医科大学学报, 2017, 40(5): 602-605. doi: 10.3969/j.issn.1009-5551.2017.05.011

    LI C C, ZHOU P, WANG S, et al. Clinical characteristics of patients with acute renal injury in intensive care unit[J]. Journal of Xinjiang Medical University, 2017, 40(5): 602-605. doi: 10.3969/j.issn.1009-5551.2017.05.011
    [4]
    HALTIA U M, HALLAMAA M, TAPPER J, et al. Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors[J]. Gynecol Oncol, 2017, 144(1): 83-89. doi: 10.1016/j.ygyno.2016.11.018
    [5]
    SCALETTA G, PLOTTI F, LUVERO D, et al. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: A systematic review[J]. Expert Rev Anticancer Ther, 2017, 17(9): 827-839. doi: 10.1080/14737140.2017.1360138
    [6]
    JIA M M, DENG J, CHENG X L, et al. Diagnostic accuracy of urine HE4 in patients with ovarian cancer: A meta-analysis[J]. Oncotarget, 2017, 8(6): 9660-9671. doi: 10.18632/oncotarget.14173
    [7]
    张剑, 董欣敏, 吴婧, 等. 血清人附睾蛋白4在肺癌诊断中的临床应用探讨[J]. 中华全科医学, 2016, 14(8): 1302-1304. doi: 10.16766/j.cnki.issn.1674-4152.2016.08.018

    ZHANG J, DONG X M, WANG J, et al. The diagnostic value of human epididymis protein 4 in lung cancer[J]. Chinese general practice, 2016, 14(8): 1302-1304. doi: 10.16766/j.cnki.issn.1674-4152.2016.08.018
    [8]
    潘凌峰, 王静, 陈永伟, 等. 血清人附睾上皮分泌蛋白4水平检测在卵巢癌的应用价值研究[J]. 国际检验医学杂志, 2019, 40(A01): 182-184. https://www.cnki.com.cn/Article/CJFDTOTAL-SFCZ201504013.htm

    PAN L F, WANG J, CHEN Y W, et al. Study on the application value of serum human epididymal epithelial secretory protein 4 level in ovarian cancer[J]. International Journal of Laboratory Medicine, 2019, 40(A01): 182-184. https://www.cnki.com.cn/Article/CJFDTOTAL-SFCZ201504013.htm
    [9]
    BÉLA N J, BÉLA N, LIBOR F, et al. Human Epididymis Protein 4: A novel serum inflammatory biomarker in cystic fibrosis[J]. Chest, 2016, 150(3): 661-672. doi: 10.1016/j.chest.2016.04.006
    [10]
    WANG J L, ZHAO H Y, XU F F, et al. Human epididymis protein 4 (HE4) protects against cystic pulmonary fibrosis associated-inflammation through inhibition of NF-κB and MAPK singnaling[J]. Genes & Genomics, 2019, 41(9): 1045-1053.
    [11]
    WAN J X, WANG Y H, CAI G R, et al. Elevated serum concentrations of HE4 as a novel biomarker of disease severity and renal fibrosis in kidney disease[J]. Oncotarget, 2016, 7(42): 67748-67759. doi: 10.18632/oncotarget.11682
    [12]
    WANG L S, SUN Y H, CAI X A, et al. The diagnostic value of human epididymis protein 4 as a novel biomarker in patients with renal dysfunction[J]. Int Urol Nephrol, 2018, 50(2): 2043-2048.
    [13]
    YANG Z X, ZHANG Z Y, QIN B D, et al. Human epididymis protein 4: A novel biomarker for lupus nephritis and chronic kidney disease in systemic lupus erythematosus[J]. J Clin Lab Anal, 2016, 30(6): 897-904. doi: 10.1002/jcla.21954
    [14]
    QIN L, MOHAN C. Non-invasive biomarkers for systemic lupus erythematosus: A lookback at 2016[J]. Int J Rheum Dis, 2016, 19(12): 1209-1215. doi: 10.1111/1756-185X.13075
    [15]
    INKER L A, ASTOR B C, FOX C H, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD[J]. Am J Kidney Dis, 2014, 63(5): 713-735. doi: 10.1053/j.ajkd.2014.01.416
    [16]
    SIMONA F, CRISTINA R, NICOLETTA T, et al. Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up[J]. Clin Biochem, 2018, 60: 84-90. doi: 10.1016/j.clinbiochem.2018.08.003
    [17]
    STIEKEMA A, LOK C, KORSE C M, et al. Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer[J]. Virchows Archiv, 2017, 470(6): 655-664. doi: 10.1007/s00428-017-2115-1
    [18]
    GUNDUZ U R, GUNALDI M, ISIKSACAN N, et al. A new marker for breast cancer diagnosis human epididymis protein 4: A preliminary study[J]. Mol Clin Oncol, 2016, 5(2): 355-360. doi: 10.3892/mco.2016.919
    [19]
    GE X, ZHANG X L, LI M, et al. The value of serum HE4 in pancreatic adenocarcinoma diagnosis[J]. Int Clinical Exp Pathol, 2017, 10(5): 5618-5623.
    [20]
    ZENG Q, LIU M Q, ZHOU N, et al. Serum human epididymis protein 4(HE4) may be a better tumor marker in early lung cancer[J]. Clinica Chimica Acta, 2016, 455(1): 102-106.
    [21]
    LEBLEU V S, TENG Y Q, O' CONNELL J T, et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis[J]. Nat Med, 2013, 19(2): 227-231. doi: 10.1038/nm.2989
    [22]
    白冰, 张冬萍, 王萍, 等. 肾移植术后CKD患者血清HE4与疾病进展分期的关系及诊断价值[J]. 国际检验医学杂志, 2019, 40(22): 2767-2770. doi: 10.3969/j.issn.1673-4130.2019.22.019

    BAI B, ZHANG D P, WANG P, et al. The relationship between serum HE4 and disease progression stage in patients with CKD after renal transplantation and its diagnostic value[J]. International Journal of Laboratory Medicine, 2019, 40(22): 2767-2770. doi: 10.3969/j.issn.1673-4130.2019.22.019
    [23]
    卢美红, 杨春兰, 景蓉蓉, 等. 血清人附睾蛋白4表达与慢性肾脏病的相关性研究[J]. 现代检验医学杂志, 2017(32): 75-77, 81. https://www.cnki.com.cn/Article/CJFDTOTAL-SXYN201702020.htm

    LU M H, YANG C L, JING R R, et al. Study on association with expression in patients with chronic kidney disease[J]. Journal of Modern Laboratory Medicine, 2017(32): 75-77, 81. https://www.cnki.com.cn/Article/CJFDTOTAL-SXYN201702020.htm
    [24]
    QU W L, LI J P, DUAN P, et al. Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies[J]. Exp Rev Mol Diagn, 2016, 16(12): 1271-1282. doi: 10.1080/14737159.2016.1251317
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Article Metrics

    Article views (177) PDF downloads(9) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return